HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
{{output}}
Background: Patients with Multiple Sclerosis (PwMS) display altered lipoproteins levels and function, which seem to affect disease risk and progress. Whether disease-modifying therapies affect the lipoprotein profile in PwMS has ... ...
